Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens

Expert Review of Vaccines

Volumn 10, Issue 2, 2011, Pages 227-251

  Dey, Antu K ^a   Srivastava, Indresh K ^a,b  

^a Novartis Vaccines and Diagnostics Inc   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

adjuvant; immunogen; MF59; MPL; nanoemulsions; PAMPs; PLG microparticles; PRR; SMIP

Indexed keywords

ADJUVANT; ALPHA INTERFERON; ANTIGEN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; HEPATITIS C VACCINE; IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOME; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; LIPOSOME; MALARIA VACCINE; MELAN A; MUMPS VACCINE; MURAMYL DIPEPTIDE; MURAMYL TRIPEPTIDE; PHOSPHORYL LIPID A; RECOMBINANT HEPATITIS B VACCINE; SAPONIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; VIROSOME VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPOTENTIATION; INFLUENZA; INNATE IMMUNITY; IONIC STRENGTH; MALARIA; MELANOMA; MEMBRANE MICROPARTICLE; MUMPS; NANOEMULSION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PH; PRIORITY JOURNAL; REVIEW; TETANUS; UTERINE CERVIX CANCER; VACCINATION; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION; VACCINES;

EID: 79951991406     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.142     Document Type: Review

References (278)

1. Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur 38, 1-7 (1924)
2. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA, 141-228 (1995)
3. Edelman R. Adjuvants for the future. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds). Marcel Dekker Inc., NY, USA, 173-192 (1997)
4. Lindblad EB. Aluminium comp (Pubitemid 39421059)
5. Lindblad EB. Aluminium adjuvant - in retrospect and prospect. Vaccine 22(27-28), 3658-3668 (2004)
6. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6(5), 699-710 (2007)
7. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59- adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359(15), 1631-1633 (2008)
8. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc. Health 44(1), 33-40 (2009)
9. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19(1), 103-107 (1999) (Pubitemid 29497759)
10. Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr. Infect. Dis. J. 26(9), 787-793 (2007) (Pubitemid 47329848)
11. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit. Rev. Biotechnol. 19(4), 317-357 (1999) (Pubitemid 30036089)
12. Krishnan L, Dennis Sprott G. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. J. Drug Target. 11(8-10), 515-524 (2003) (Pubitemid 38519161)
13. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68(1), 54-63 (2000) (Pubitemid 30016677)
14. Mishra N, Goyal AK, Tiwari S, et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin. Ther. Pat. 20(5), 661-679 (2010)
15. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin Immunol. 21(1), 23-29 (2009)
16. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27(5), 687-690 (2007) (Pubitemid 350102263)
17. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156, 199-209 (1997) (Pubitemid 27197203)
18. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989) (Pubitemid 20177564)
19. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [see comments]. Nature 388(6640), 394-397 (1997) (Pubitemid 27334820)
20. Fearon DT. Seeking wisdom in innate immunity. Nature 388(6640), 323-324 (1997) (Pubitemid 27334792)
21. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 272(5258), 50-53 (1996)
22. Yip HC, Karulin AY, Tary-Lehmann M, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162(7), 3942-3949 (1999) (Pubitemid 29314773)
23. Ribi E, Amano K, Cantrell JL, Schwartzman S, Parker R, Takayama K. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother. 12, 91-96 (1982) (Pubitemid 12192020)
24. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained form the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257(19), 11808-11815 (1982) (Pubitemid 13218648)
25. Baker PJ, Haslov KR, Fauntleroy MB, Stashak PW, Myers K, Ulrich JT. Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect. Immun. 58(3), 726-731 (1990) (Pubitemid 20072637)
26. Brunner R, Wallmann J, Szalai K, et al. The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy 37(10), 1566-1573 (2007) (Pubitemid 47460239)
27. Domer JE, Human LG, Andersen GB, Rudbach JA, Asherson GL. Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A. Infect. Immun. 61(5), 2122-2130 (1993) (Pubitemid 23145922)
28. Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon g as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143(5), 483-488 (1992)
29. Schneerson R, Fattom A, Szu SC, et al. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 147(7), 2136-2140 (1991)
30. Garg M, Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant. Infect. Immun. 60(6), 2329-2336 (1992)
31. Ambrosch F, Wiedermann G, Kundi M, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 18(20), 2095-2101 (2000) (Pubitemid 30129098)
32. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA 89(1), 358-362 (1992)
33. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12(8), 683-693 (1996) (Pubitemid 26138746)
34. Le TP, Church LW, Corradin G, et al. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16(2-3), 305-312 (1998) (Pubitemid 27521015)
35. Schultz N, Oratz R, Chen D, Zeleniuch- Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13(5), 503-508 (1995)
36. Mitchell AD, Myhr BC, Rudd CJ, Caspary WJ, Dunkel VC. Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: methods used and chemicals evaluated. Environ. Mol. Mutagen. 12(Suppl. 13), 1-18 (1988)
37. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883-5893 (1988)
38. MacLean GD, Bowen-Yacyshyn MB, Samuel J, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen- Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 11(4), 292-305 (1992)
39. MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 36(4), 215-222 (1993) (Pubitemid 23069240)
40. Rickman LS, Gordon DM, Wistar R Jr, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 337(8748), 998-1001 (1991)
41. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein- hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576-1585 (1995)
42. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56(6), 498-505 (2001) (Pubitemid 32521429)
43. Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev. Vaccines 5(5), 617-629 (2006) (Pubitemid 46021044)
44. Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid L. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacol. 17(2), 117-131 (1995)
45. Palache AM, Beyer WE, Hendriksen E, et al. Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Vaccine 14(14), 1327-1330 (1996)
46. Hart MK, Palker TJ, Matthews TJ, et al. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 145(8), 2677-2685 (1990) (Pubitemid 20374595)
47. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60(2), 662-668 (1992)
48. Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170(5), 1288-1291 (1994)
49. Namba K, Nakajima R, Otani T, Azuma I. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine 14(12), 1149-1153 (1996) (Pubitemid 26348834)
50. Namba K, Nitanai H, Otani T, Azuma I. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Vaccine 14(14), 1322-1326 (1996) (Pubitemid 27008192)
51. Kaji M, Kaji Y, Kaji M, et al. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine 10(10), 663-667 (1992)
52. van den Akker F, Sarfaty S, Twiddy EM, Connell TD, Holmes RK, Hol WG. Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure 4(6), 665-678 (1996) (Pubitemid 126661290)
53. Vajdy M, Singh M, Ugozzoli M, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 110(1), 86-94 (2003) (Pubitemid 37059676)
54. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56(4), 622-647 (1992)
55. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5), 1617-1623 (1995)
56. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65(7), 2821-2828 (1997) (Pubitemid 27264113)
57. Douce G, Giannelli V, Pizza M, et al. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67(9), 4400-4406 (1999) (Pubitemid 29400413)
58. Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64(3), 974-979 (1996) (Pubitemid 26069681)
59. Giannelli V, Fontana MR, Giuliani MM, Guangcai D, Rappuoli R, Pizza M. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 65(1), 331-334 (1997) (Pubitemid 27008943)
60. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187, 1123-1132 (1998) (Pubitemid 28176412)
61. Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 17(7-8), 695-704 (1999) (Pubitemid 29074723)
62. Vajdy M, Singh M, Kazzaz J, et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 20(11), 1269-1281 (2004) (Pubitemid 39557877)
63. Srivastava IK, Stamatatos L, Kan E, et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77(20), 11244-11259 (2003) (Pubitemid 37204314)
64. Zhou F, Goodsell A, Uematsu Y, Vajdy M. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant. Clin. Vaccine Immunol. 16(4), 471-478 (2009)
65. Vajdy M, Baudner B, Del Giudice G, O'Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin. Immunol. 123(2), 166-175 (2007) (Pubitemid 46590074)
66. Goodsell A, Zhou F, Gupta S, et al. b7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 123(3), 378-389 (2008) (Pubitemid 351171190)
67. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382(2), 217-225 (2008)
68. Barnett SW, Srivastava IK, Kan E, et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22(3), 339-348 (2008)
69. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 391(6670), 851 (1998) (Pubitemid 28157653)
70. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403-1406 (2000) (Pubitemid 32001027)
71. Barackman JD, Ott G, Pine S, O'Hagan DT. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 8(3), 652-657 (2001) (Pubitemid 32428899)
72. Ryan EJ, McNeela E, Murphy GA, et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67(12), 6270-6280 (1999)
73. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 67(11), 5892-5897 (1999) (Pubitemid 29508115)
74. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control Release 67(2-3), 347-356 (2000) (Pubitemid 30303847)
75. Colwell WM, Simmons DG, Harris JR, Fulp TG, Carrozza JH, Maag TA. Influence of some physical factors on survival of Marek's disease vaccine virus. Avian Dis. 19(4), 781-790 (1975)
76. Singh M, Vajdy M, Gardner J, Briones M, O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 20(3-4), 594-602 (2001) (Pubitemid 32973805)
77. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147(6), 1759-1764 (1991)
78. Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl Cancer Inst. 72(4), 955-962 (1984) (Pubitemid 14131740)
79. Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5(4), 241 (1995) (Pubitemid 26041389)
80. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995)
81. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFNg. Proc. Natl Acad. Sci. USA 93(7), 2879-2883 (1996) (Pubitemid 26116242)
82. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial-DNA induces murine interferon-g production by stimulation of interleukin-12 and tumor-necrosis-factor-a. Cell. Immunol. 167(1), 72-78 (1996) (Pubitemid 26048848)
83. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-g promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol. 156(2), 558-564 (1996)
84. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298(5601), 2199-2202 (2002) (Pubitemid 35471246)
85. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782-787 (2000)
86. Thomas LJ, Hammond RA, Forsberg EM, et al. Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum. Vaccin. 5(2), 79-84 (2009)
87. Malaspina A, Moir S, DiPoto AC, et al. CpG oligonucleotides enhance proliferative and effector responses of B cells in HIV-infected individuals. J. Immunol. 181(2), 1199-1206 (2008)
88. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 21(6), 387-401 (2007) (Pubitemid 350145447)
89. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167(7), 3555-3558 (2001) (Pubitemid 32910795)
90. Bauer M, Redecke V, Ellwart JW, et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol. 166(8), 5000-5007 (2001) (Pubitemid 32280712)
91. Cazeaux N, Bennasser Y, Vidal PL, Li Z, Paulin D, Bahraoui E. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine 20(27-28), 3322-3331 (2002) (Pubitemid 35245816)
92. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158(8), 3635-3639 (1997) (Pubitemid 127488716)
93. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3(1), 15-24 (2001) (Pubitemid 32177965)
94. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75(12), 5526-5540 (2001) (Pubitemid 32488146)
95. Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 8(2), 181-184 (1998) (Pubitemid 28223342)
96. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161(5), 2428-2434 (1998) (Pubitemid 28397058)
97. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13(11), 1006-1012 (1995)
98. Kovarik J, Bozzotti P, Love-Homan L, et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162(3), 1611-1617 (1999) (Pubitemid 29307036)
99. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161(9), 4463-4466 (1998) (Pubitemid 28492011)
100. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 95(26), 15553-15558 (1998) (Pubitemid 29018737)
101. Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19(13-14), 1636-1642 (2001) (Pubitemid 32175723)
102. Horner AA, Ronaghy A, Cheng PM, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190(1), 77-82 (1998)
103. McCluskie MJ, Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19(4-5), 413-422 (2000)
104. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 17(1), 19-25 (1999) (Pubitemid 28470728)
105. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161(12), 7054-7062 (1998) (Pubitemid 28562256)
106. Burke B, Gomez-Roman VR, Lian Y, et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 387(1), 147-156 (2009)
107. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146(2), 431-437 (1991)
108. Glaueri AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature 196, 953 (1962)
109. Powell MF, Cleland JL, Eastman DJ, et al. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons [published erratum appears in AIDS Res. Hum. Retroviruses 1995 May; 11(5), 661]. AIDS Res. Hum. Retroviruses 10(Suppl. 2), S105-S108 (1994)
110. Kensil CR, Barrett C, Kushner N, et al. Development of a genetically engineered vaccine against feline leukemia virus infection. J. Am. Vet. Med. Assoc. 199(10), 1423-1427 (1991)
111. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 27(12), 1787-1796 (2009)
112. Kircheis R, Vondru P, Zinocker I, et al. Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells. Vaccine 24(13), 2349-2357 (2006) (Pubitemid 43290417)
113. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007) (Pubitemid 47607848)
114. Garcon N, Goldman M. Boosting vaccine power. Sci. Am. 301(4), 72-79 (2009)
115. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 667, 111-123 (2010)
116. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308(5958), 457-460 (1984) (Pubitemid 14130919)
117. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 20(1-2), 158-163 (2001) (Pubitemid 32905328)
118. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17(11-12), 1355-1358 (1999) (Pubitemid 29138801)
119. Villacres-Eriksson M, Bergstrom- Mollaoglu M, Kaberg H, Lovgren K, Morein B. The induction of cell-associated and secreted IL-1 by iscoms, matrix or micelles in murine splenic cells. Clin. Exp. Immunol. 93(1), 120-125 (1993) (Pubitemid 23195950)
120. Ozel M, Hoglund S, Gelderblom HR, Morein B. Quaternary structure of the immunostimulating complex (ISCOM). J. Ultrastruct. Mol. Struct. Res. 102(3), 240-248 (1989) (Pubitemid 20125457)
121. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 27(2), 241-245 (1988)
122. Jones LS, Cipolla D, Liu J, Shire SJ, Randolph TW. Investigation of protein- surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharm. Res. 16(6), 808-812 (1999) (Pubitemid 29284189)
123. Thaparr MA, Parr EL, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 9(2), 129-133 (1991)
124. Rimmelzwaan GF, Osterhaus A. Cytotoxic T-lymphocyte memory - role in cross-protective immunity against influenza. Vaccine 13(8), 703-705 (1995)
125. Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 13(14), 1375-1382 (1995)
126. Sundquist B, Lovgren K, Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine 6(1), 49-53 (1988) (Pubitemid 18042684)
127. Brey RN. Development of vaccines based on formulations containing nonionic block copolymers. Pharm. Biotechnol. 6, 297-311 (1995)
128. Bennett B, Check IJ, Olsen MR, Hunter RL. A comparison of commercially available adjuvants for use in research. J. Immunol. Methods 153(1-2), 31-40 (1992)
129. Howerton DA, Hunter RL, Ziegler HK, Check IJ. Induction of macrophage Ia expression in vivo by a synthetic block copolymer, L81. J. Immunol. 144(5), 1578-1584 (1990) (Pubitemid 20093983)
130. Heath AW. Cytokines as immunological adjuvants. Pharm. Biotechnol. 6, 645-658 (1995)
131. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68(2), 122-138 (1998) (Pubitemid 28269982)
132. Pettit DK, Lawter JR, Huang WJ, et al. Characterization of poly(glycolide-co-d,l-lactide)/poly(d,l-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 14(10), 1422-1430 (1997) (Pubitemid 27481074)
133. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60(14), 3832-3837 (2000) (Pubitemid 32204575)
134. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl.), S63-S68 (2005) (Pubitemid 40562305)
135. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol. 24(6), 693-701 (2004) (Pubitemid 40933121)
136. Mason KA, Ariga H, Neal R, et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. 11(1), 361-369 (2005) (Pubitemid 40075816)
137. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol. 149(Suppl. 66), 15-19 (2003) (Pubitemid 38064508)
138. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002) (Pubitemid 34141451)
139. Asai Y, Ohyama Y, Gen K, Ogawa T. Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2. Infect. Immun. 69(12), 7387-7395 (2001) (Pubitemid 33086563)
140. Chernysh S, Kim SI, Bekker G, et al. Antiviral and antitumor peptides from insects. Proc. Natl Acad. Sci. USA 99(20), 12628-12632 (2002)
141. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95(2), 157-168 (1986) (Pubitemid 17229409)
142. Lindblad EB. Freund's adjuvants. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan DT (Ed.). Humana Press, NJ, USA, 49-63 (2000)
143. Lindblad EB, Hau J. Escaping from the use of Freund's complete adjuvant. In: Progress in the Reduction Refinement and Replacement of Animal Experimentation. Balls M, van Zeller A-M, Halder ME (Eds). Elsevier Science, Amsterdam, The Netherlands, 1681-1685 (2000)
144. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2(2), 197-203 (2003)
145. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995)
146. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14(6), 478-484 (1996)
147. Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly(d,l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J. Control. Release 66(2-3), 229-241 (2000) (Pubitemid 30160860)
148. Heineman TC, Clements-Mann ML, Poland GA, et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769-2778 (1999) (Pubitemid 29323002)
149. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59- adjuvanted influenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999) (Pubitemid 29366990)
150. Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol. 15(6), 573-576 (1999) (Pubitemid 29400033)
151. Cunningham CK, Wara DW, Kang M, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis. 32(5), 801-807 (2001) (Pubitemid 32221940)
152. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183(4), 563-570 (2001)
153. Makidon PE, Bielinska AU, Nigavekar SS, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 3(8), e2954 (2008)
154. Hamouda T, Chepurnov A, Mank N, et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum. Vaccin. DOI: 10.4161/hv.6.7.11818 (2010) (Epub ahead of print)
155. Bielinska AU, Chepurnov AA, Landers JJ, et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin. Vaccine Immunol. 15(2), 348-358 (2008) (Pubitemid 352025538)
156. Bielinska AU, Janczak KW, Landers JJ, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 75(8), 4020-4029 (2007) (Pubitemid 47206301)
157. Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24(2), 271-281 (2008) (Pubitemid 351282102)
158. Bielinska AU, Gerber M, Blanco LP, et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit. Rev. Immunol. 30(2), 189-199 (2010)
159. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12(1), 1-99 (1995)
160. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16 [published erratum appears in Nat. Biotechnol. 16(5), 478 (1998)](2), 153-157 (1998)
161. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59(9), 2978-2986 (1991)
162. O'Hagan DT. HIV and mucosal immunity. Lancet 337(8752), 1289 (1991)
163. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81(4), 661-667 (1994) (Pubitemid 24246520)
164. Moore A, McGuirk P, Adams S, et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13(18), 1741-1749 (1995) (Pubitemid 26013110)
165. Nixon DF, Hioe C, Chen PD, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 14(16), 1523-1530 (1996) (Pubitemid 27023496)
166. Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9(4), 356-362 (1988)
167. Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res. 22(10), 837-858 (1988)
168. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11(6), 753-761 (1999) (Pubitemid 30030714)
169. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 19(10), 1480-1487 (2002) (Pubitemid 35266552)
170. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 60(3), 480-486 (2002)
171. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft- poly(lactide-co-glycolide), evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18(3), 352-360 (2001) (Pubitemid 32595824)
172. Seder RA, Gurunathan S. DNA vaccines - designer vaccines for the 21st Century. N. Engl. J. Med. 341(4), 277-278 (1999)
173. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112), 1320-1325 (1998) (Pubitemid 28195910)
174. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292(5514), 69-74 (2001) (Pubitemid 32289126)
175. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397-402 (1998) (Pubitemid 28212753)
176. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812), 605-609 (2000)
177. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 4, 365-368 (1998) (Pubitemid 28144100)
178. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 88(1), 126-130 (1999) (Pubitemid 29037379)
179. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(dl-lactide-co-glycolide), stability issues and release characteristics. J. Control. Release 61(3), 361-374 (1999) (Pubitemid 29413030)
180. Otten GR, Schaefer M, Doe B, et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol. 79(13), 8189-8200 (2005) (Pubitemid 40853522)
181. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7(24), 2105-2112 (2000) (Pubitemid 32118079)
182. O'Hagan DT, Singh M, Kazzaz J, et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20(27-28), 3389-3398 (2002) (Pubitemid 35245822)
183. Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 39(9), 698-704 (1987) (Pubitemid 18015453)
184. Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control. Release 69(1), 69-80 (2000)
185. Cleland JL, Barron L, Daugherty A, et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. 85(12), 1350-1357 (1997) (Pubitemid 27014193)
186. Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16(19), 1822-1827 (1998) (Pubitemid 28473922)
187. Singh M, Li XM, McGee JP, et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 15(5), 475-481 (1997) (Pubitemid 27188615)
188. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O'Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76(1), 164-168 (1992)
189. Challacombe SJ, Rahman D, O'Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 15(2), 169-175 (1997) (Pubitemid 27091247)
190. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 11, 205-214 (1990) (Pubitemid 20070098)
191. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19(15-16), 1940-1950 (2001) (Pubitemid 32178342)
192. Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(dl-lactide-co-glycolide) microspheres. Infect. Immun. 63(4), 1195-1200 (1995)
193. Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat. Med. 2(10), 1116-1121 (1996) (Pubitemid 26338631)
194. Allaoui-Attarki K, Pecquet S, Fattal E, et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(dl-lactide-co-glycolide) microspheres. Infect. Immun. 65(3), 853-857 (1997) (Pubitemid 27087981)
195. Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin encapsulated in microspheres. Infect. Immun. 70(3), 1143-1149 (2002) (Pubitemid 34163385)
196. Kende M, Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 20(11-12), 1681-1691 (2002) (Pubitemid 34169812)
197. Marx PA, Compans RW, Gettie A, et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260(5112), 1323-1327 (1993) (Pubitemid 23231976)
198. Tseng J, Komisar JL, Trout RN, et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect. Immun. 63(8), 2880-2885 (1995)
199. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386(6623), 410-414 (1997) (Pubitemid 27154483)
200. Eyles JE, Spiers ID, Williamson ED, Alpar HO. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J. Pharm. Pharmacol. 53(5), 601-607 (2001) (Pubitemid 32457810)
201. Lambert JS, Keefer M, Mulligan MJ, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 19(23-24), 3033-3042 (2001) (Pubitemid 32324030)
202. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108(3), 241-247 (2003) (Pubitemid 37117370)
203. Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci. 14(3), 183-189 (2001) (Pubitemid 32884313)
204. Butts C, Murray N, Maksymiuk A, et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005) (Pubitemid 46190262)
205. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines 4(3), 249-257 (2005) (Pubitemid 40978689)
206. Sangha R, North S. L-BLP25: a MUC1- targeted peptide vaccine therapy in prostate cancer. Expert Opin. Biol. Ther. 7(11), 1723-1730 (2007) (Pubitemid 350157497)
207. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 252(5480), 252 (1974)
208. Gregoriadis G, Putman D, Louis L, Neerunjun D. Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem. J. 140(2), 323-330 (1974)
209. Alving CR. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 140(1), 1-13 (1991)
210. Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187(3-5), 430-446 (1993) (Pubitemid 23150783)
211. van Rooijen N, van Nieuwmegen R. Liposomes in immunology: evidence that their adjuvant effect results from surface exposition of the antigens. Cell. Immunol. 49(2), 402-407 (1980) (Pubitemid 10214929)
212. Gregoriadis G. Liposomes, a tale of drug targeting. J. Drug Target 1(1), 3-6 (1993)
213. Reddy R, Zhou F, Huang L, Carbone F, Bevan M, Rouse BT. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods 141(2), 157-163 (1991)
214. Hedlund G, Jansson B, Sjogren HO. Comparison of immune responses induced by rat RT-1 antigens presented as inserts into liposomes, as protein micelles and as intact cells. Immunology 53(1), 69-78 (1984) (Pubitemid 14057692)
215. Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 5(2), 145-151 (1987) (Pubitemid 17092721)
216. Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv. Exp. Med. Biol. 238, 151-159 (1988)
217. Davis D, Davies A, Gregoriadis G. Liposomes as adjuvants with immunopurified tetanus toxoid: the immune response. Immunol. Lett. 14(4), 341-348 (1987) (Pubitemid 17055205)
218. Antimisiaris SG, Jayasekera P, Gregoriadis G. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles. J. Immunol. Methods 166(2), 271-280 (1993)
219. Altin JG, Parish CR. Liposomal vaccines - targeting the delivery of antigen. Methods 40(1), 39-52 (2006) (Pubitemid 44415497)
220. Felnerova D, Viret JF, Gluck R, et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15, 518-529 (2004) (Pubitemid 39551004)
221. Sato Y, Murase K, Kato J, et al. Resolution of rat liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen specific chaperon. Nat. Biotechnol. 26, 431-442 (2008) (Pubitemid 351501817)
222. Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90(6), 2491-2495 (1992) (Pubitemid 23010069)
223. Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 20(Suppl. 5), B10-B16 (2002) (Pubitemid 35435391)
224. Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 17(13-14), 1782-1787 (1999) (Pubitemid 29138918)
225. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20(Suppl. 5), B17-B23 (2002) (Pubitemid 35435392)
226. Alving CR. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann NY Acad. Sci. 754, 143-152 (1995)
227. Gluck R, Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 21(7-8), 611-615 (2003) (Pubitemid 36091969)
228. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56, 365-394 (1987)
229. Jackson DC, Crabb BS, Poumbourios P, Tulip WR, Laver WG. Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin. Arch. Virol. 116(1-4), 45-56 (1991)
230. Lowell GH, Smith LF, Seid RC, Zollinger WD. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med. 167(2), 658-663 (1988) (Pubitemid 18073663)
231. O'Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine 7(3), 213-216 (1989) (Pubitemid 19174455)
232. Freund J. The mode of action of immunologic adjuvants. Bibl. Tuberc. 10, 130-148 (1956)
233. Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr. Drug Deliv. 2(4), 395-400 (2005) (Pubitemid 41277771)
234. Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. 4(7), 1139-1145 (2004) (Pubitemid 38937555)
235. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006) (Pubitemid 44415499)
236. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 23(Suppl. 1), S26-S38 (2005)
237. Shouval D, Ilan Y, Adler R, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12(15), 1453-1459 (1994)
238. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing pre-S components of the coat protein - a preliminary study on immunogenicity. Vaccine 10(7), 439-442 (1992)
239. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72(2), 1345-1353 (1998) (Pubitemid 28116920)
240. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72(11), 6519-6527 (2004) (Pubitemid 39425433)
241. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun. 73(6), 3587-3597 (2005) (Pubitemid 40745903)
242. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol. 6, 229-248 (1995)
243. Volkin D, Middaugh C. Stability of Protein Pharmaceuticals Part A - Chemical and Physical Pathways of Protein Degradation. Plenum Press, NY, USA (1992)
244. Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys. J. 47(3), 411-414 (1985)
245. Middaugh CR. Advances in the delivery of pharmaceuticals. J. Pharm. Sci. 87(11), 1265-1266 (1998) (Pubitemid 28514125)
246. Middaugh CR, Edwards KL. Recent advances in our understanding of protein conformational stability from a pharmaceutical perspective. Expert Opin. Investig. Drugs 7(9), 1493-1500 (1998)
247. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 8(5), 1028-1037 (2002) (Pubitemid 34517636)
248. Toda S, Ishii N, Okada E, et al. HIV-1- specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-g antibody. Immunology 92(1), 111-117 (1997) (Pubitemid 27380889)
249. Giannasca PJ, Boden JA, Monath TP. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect. Immun. 65(10), 4288-4298 (1997) (Pubitemid 27422090)
250. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 16(5), 536-541 (1998) (Pubitemid 28044172)
251. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res. 14(5), 613-618 (1997) (Pubitemid 27220279)
252. Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185(5), 686-690 (2002) (Pubitemid 34171475)
253. Agren L, Sverremark E, Ekman L, et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164(12), 6276-6286 (2000) (Pubitemid 30408808)
254. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158(8), 3936-3946 (1997) (Pubitemid 127488754)
255. Agren LC, Ekman L, Lowenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162(4), 2432-2440 (1999) (Pubitemid 29288873)
256. Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl Acad. Sci. USA 94(22), 12059-12064 (1997) (Pubitemid 27467842)
257. Davis MM, Butchart AT, Coleman MS, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 28(5), 1353-1356 (2010)
258. Voss G, Manson K, Montefiori D, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J. Virol. 77(2), 1049-1058 (2003) (Pubitemid 36055526)
259. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77(11), 6305-6313 (2003) (Pubitemid 36588400)
260. Vajdy M SM, Medina-Selby A, Coit D, et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol. 87, 2253-2262 (2006) (Pubitemid 44178102)
261. Barnett SW, Rajasekar S, Legg H, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15(8), 869-873 (1997) (Pubitemid 27287978)
262. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174(6), 1168-1175 (1996) (Pubitemid 26393893)
263. Peng B, Voltan R, Cristillo AD, et al. Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS 20(17), 2149-2157 (2006) (Pubitemid 44684705)
264. Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24(16), 3063-3065 (2006)
265. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R. MF59- adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25(20), 3955-3961 (2007) (Pubitemid 46616991)
266. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A Phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 18(15), 1448-1455 (2000) (Pubitemid 30017825)
267. Keeney RT, Edelman R. Survey of human-use adjuvants. Expert Rev. Vaccines 2, 167-188 (2003) (Pubitemid 36559923)
268. Podda A, Del Giudice G. MF59- adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2, 197-203 (2003)
269. Mengiardi B, Berger R, Just M, et al. Virosomes as carriers for combined vaccines. Vaccines 13, 1306-1315 (1995)
270. Poltl-Frank F, Zubriggen R, Helg A, et al. Use of reonstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide based vaccine. Clin. Exp. Immunol. 117, 496-503 (1999) (Pubitemid 29398296)
271. Hunziker IP, Zubriggen R, Gluck R, et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38, 475-484 (2001) (Pubitemid 34008477)
272. Cusi MG, Zubriggen R, Correale P, et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus- F antigen inducing humoral and cell-mediated immunity. Vaccine 20, 3436-3442 (2002) (Pubitemid 35248067)
273. Cusi MG, Zubriggen R, Valassina M, et al. Intranasal immunization with Mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology 277, 111-118 (2000)
274. WHO Expanded Programme on Immunization (EPI) www.who.int/immunization- delivery/en
275. Liposomes based transfecting agents marketed by Hokkaido System Science Co. Ltd www.hssnet.co.jp/index.html
276. Immunization Action Coalition: vaccines and biologics used in US and foreign markets (Item #P5120) www.immunize.org
277. Vaccines in clinical trials. www.clinicaltrials.gov
278. Vaccines approved for human use www.fda.gov/BiologicsBloodVaccines/ Vaccines